D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1

• DOI: 10.1073/pnas.2114851119
• Publication Date: 2022-02-18T21:00:54Z
• Authors: Ruonan Zhang; Yajing Yang; Wenjing Dong; Mingen Lin; Jing He; Xinchao Zhang; Tongguan Tian; Yunlong Yang; Kun Chen; Qun-Ying Lei; Song Zhang; Yanping Xu; Lei Lv
• Keywords: Triple-negative breast cancer; Degradation; Cancer Immunotherapy

Significance PD-L1 is well known as an immune checkpoint molecule, which suppresses surveillance through binding to its receptor PD-1. Intracellular can also protect messenger RNAs of several DNA damage repair–related genes from degradation and enhance tumor resistance DNA-damaging therapy. Triple-negative breast cancer (TNBC) has the worst prognosis highest risk distant relapse in shows immunotherapy radiotherapy. In this study, we found that D-mannose promote significantly radiotherapy TNBC. Since TNBC treatment still a clinical challenge, our findings provide strategies therapeutic efficacy may have application.